Dr. Rosenberg brings to Verrica more than 30 years of clinical and therapeutic development experience. He has led multiple global drug approvals across a number of therapeutic areas, including dermatology.

Dr. Rosenberg has served as chief medical officer for several public and private biotech companies, and has been responsible for the clinical development and medical strategy for pipeline candidates and multiple product launches. He most recently served as CMO at Travere Therapeutics, leading the team responsible for the successful approval of Filspari, and previously led development of Xepi, a topical antibiotic for the treatment of impetigo, at Medimetriks. Earlier in his career, Dr. Rosenberg held leadership positions with Esperion Therapeutics, Forest Research Institute, Sanofi Aventis and Pfizer, where he focused on cardiovascular/metabolism drug development.

Dr. Rosenberg completed his internal medicine residency at the Icahn School of Medicine at Mount Sinai. Dr. Rosenberg holds an M.D. from Drexel University College of Medicine and received his B.A. from Johns Hopkins University.